Clinical Research on Heavy-Ion Low-Dose Therapy

Clinical Research on Heavy-Ion Low-Dose Therapy with Zero Out-of-Pocket Costs for Benign Prostatic Hyperplasia Fully Launched

Gansu Wuwei Cancer Hospital, as the first hospital in China to clinically apply a heavy-ion system and the only hospital in the world operating two heavy-ion systems, has treated over 2,600 patients in five years of clinical practice. The treatments cover more than 50 disease types, including lung cancer, pancreatic cancer, and liver cancer, with clinical efficacy and patient survival rates reaching internationally advanced levels. The hospital has achieved "eight world and domestic firsts":  

1. The only hospital in the world operating two heavy-ion treatment systems.  

2. The hospital with the largest number of single-fraction treatments completed within one day globally.  

3. The first hospital in the world to pioneer precision heavy-ion therapy under respiratory gating control.  

4. The first hospital in the world to perform bladder cancer treatment under precise bladder volume control.  

5. The first hospital in the world to complete single-session heavy-ion therapy using surgically implanted spacers between organs and tumors.  

6. The first hospital in China to develop a 360° rotatable and adjustable ion therapy chair.  

7. The first hospital in the world to complete heavy-ion therapy for multiple cases of cardiac tumors.  

8. The first hospital in the world to implement heavy-ion therapy combined with comprehensive, whole-lifecycle physical and mental health management.

With the aging population, the incidence of benign prostatic hyperplasia (BPH) among middle-aged and elderly men continues to rise, making it one of the common conditions affecting men's quality of life. To further advance the high-quality development of heavy-ion therapy in China, and building on previous work, we are deepening clinical application research and fully promoting the iterative upgrade of heavy-ion treatment technology. Currently, the Urology Department of the Heavy-Ion Center at Gansu Wuwei Cancer Hospital, in collaboration with the Sixth Department of Radiation Therapy, is conducting a clinical study titled "Efficacy and Safety of Low-Dose Radiotherapy for Patients with Benign Prostatic Hyperplasia."

The project aims to improve the clinical symptoms and quality of life of patients with benign prostatic hyperplasia. By benchmarking international standards, it seeks to establish clinical treatment guidelines for benign prostatic hyperplasia using China's heavy-ion system, with the goal of achieving better patient outcomes. The project has passed scientific review for clinical trial research and approval by the medical ethics committee, and is now openly recruiting participants.

Clinical Study on the Efficacy and Safety of Low-Dose Radiotherapy for Patients with Benign Prostatic Hyperplasia

Inclusion Criteria

· Aged between 60 and 85 years;  

· Presence of moderate to severe lower urinary tract symptoms, defined as an IPSS ≥ 8, and confirmed as benign prostatic hyperplasia by prostate ultrasound examination;  

· Poor symptom improvement after at least 3 months of standardized drug therapy, intolerance to adverse drug reactions, patient refusal of surgical treatment, or inability to tolerate surgery due to underlying conditions such as cardiovascular, pulmonary, or cerebral diseases;  

· In good general condition, without organ function limitations, and able to tolerate the treatment;  

· Voluntarily participate in the study and able to cooperate to complete the treatment and follow-up.
Note: The above conditions serve as the primary screening criteria. Final enrollment eligibility will be determined by the investigator based on the trial protocol.

Patient Rights

1. The hospital will provide research funding to the expert team to cover the patient's heavy-ion treatment costs.  

2. A multidisciplinary expert team (MDT) from urology and radiation oncology departments will develop a personalized treatment plan.  

3. After treatment, we will conduct close follow-up and provide you with subsequent treatment plans.

Contact Information

Gansu Wuwei Cancer Hospital, Wuwei Heavy Ion Center  

Director Juntian Tang (Urology Department) : +86 13639352510  

Director Weizuo Chen (Radiotherapy Department 6) : +86 13519351968